AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand 

THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that , participated in the .

For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s innovative technology.

The on-demand video webcast is now available on the as well as the  page under the  section of the Company’s website ().

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908.824.0775



EN
22/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Y...

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand  THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that , participated in the . For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight int...

 PRESS RELEASE

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Pr...

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise (or prepayment of the exercise price) of certain outstanding warrants to purchase up to an aggregate of 1,477,596 shares of common stock of the Company originally issued in November 2024 at a reduced exercise pri...

 PRESS RELEASE

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally I...

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advanci...

 PRESS RELEASE

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segme...

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company’s recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial. The CEO Corner segment is now available .About Autonomix Medical, Inc...

 PRESS RELEASE

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expan...

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch